Theron Pharmaceuticals is a leading biotechnology company focused on the development of innovative treatments for chronic respiratory diseases. With a focus on chronic obstructive pulmonary disease (COPD) and severe asthma, Theron aims to improve the lives of patients by creating a best-in-class, long-acting M3 muscarinic antagonist (LAMA). Theron's LAMA program centers around the development of a once-daily inhaled bronchodilator that offers broad inhalation device flexibility.

This means that their product can be used with various inhalation devices such as dry powder inhalers (DPIs), metered-dose inhalers (MDIs), and nebulizers. Additionally, Theron focuses on co-formulation compatibility, allowing their product to be combined with other drugs for multi-drug combination therapy. Their lead development candidate, TRN-157, represents a significant commercial opportunity.

It possesses the superb clinical pharmacology of the current standard-of-care LAMA, Tiotropium, while also offering the ability to be combined with other drugs and used with different inhalation devices. This promises to simplify disease management and improve clinical outcomes for COPD and severe asthma patients. With a team of experienced founders and a network of scientific advisors, Theron Pharmaceuticals is at the forefront of respiratory drug discovery and development.

Their goal is to create novel therapies that revolutionize the treatment of chronic respiratory diseases